|
1
|
Cuneo A, Scarfò L, Reda G, Varettoni M,
Quaglia FM, Marchetti M, De Paoli L, Re F, Pietrasanta D, Rigolin
GM, et al: Chronic lymphocytic leukemia management in Italy during
the COVID-19 pandemic: A Campus CLL report. Blood. 136:763–766.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eichhorst B, Robak T, Montserrat E, Ghia
P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen
P, et al: Chronic lymphocytic leukaemia: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
32:23–33. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riches JC and Gribben JG: Understanding
the immunodeficiency in chronic lymphocytic leukemia: Potential
clinical implications. Hematol Oncol Clin North Am. 27:207–235.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fürstenau M, Langerbeins P, De Silva N,
Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K,
Droogendijk J, van der Klift M, et al: COVID-19 among fit patients
with CLL treated with venetoclax-based combinations. Leukemia.
34:2225–2229. 2020. View Article : Google Scholar
|
|
5
|
Paneesha S, Pratt G, Parry H and Moss P:
Covid-19 infection in therapy-naive patients with B-cell chronic
lymphocytic leukemia. Leuk Res. 93:1063662020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Williams AM, Baran AM, Meacham PJ, Feldman
MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM
and Zent CS: Analysis of the risk of infection in patients with
chronic lymphocytic leukemia in the era of novel therapies. Leuk
Lymphoma. 59:625–632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sehn LH, Kuruvilla P, Christofides A and
Stakiw J: Management of chronic lymphocytic leukemia in Canada
during the coronavirus pandemic. Curr Oncol. 27:e332–e335. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Charra B, Ellouadghiri A, Magramane A,
Kebbou T, Damaan K, Maghfour A, Seddiki K and Ezzouine H: COVID-19
and fortuitous discovery of chronic lymphocytic leukemia:
Biological findings and therapeutic challenges. Pan Afr Med J.
36:2862020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koffman B, Mato A, Byrd JC, Danilov A,
Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM and
Shadman M: Management of CLL patients early in the COVID-19
pandemic: An international survey of CLL experts. Am J Hematol.
95:E199–E203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Strati P and Shanafelt TD: Monoclonal
B-cell lymphocytosis and early-stage chronic lymphocytic leukemia:
Diagnosis, natural history, and risk stratification. Blood.
126:454–462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thibaud S, Tremblay D, Bhalla S, Zimmerman
B, Sigel K and Gabrilove J: Protective role of Bruton tyrosine
kinase inhibitors in patients with chronic lymphocytic leukaemia
and COVID-19. Br J Haematol. 190:e73–e76. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanchez-Pina JM, Rodríguez Rodriguez M,
Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, Paciello
ML, Zafra D, Garcia-Sanchez C, Villegas C, et al: Clinical course
and risk factors for mortality from COVID-19 in patients with
haematological malignancies. Eur J Haematol. 105:597–607. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Molina-Cerrillo J, Marquet-Palomanes J,
Alonso-Gordoa T, López-Jiménez J and Grande E: May ibrutinib have
activity in respiratory complications by SARS-CoV-2? Clinical
experience in a patient with chronic lymphocytic leukemia.
Healthcare (Basel). 9:782021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scarfò L, Chatzikonstantinou T, Rigolin
GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA,
Hernandez-Rivas JÁ, Mirás F, Baile M, et al: COVID-19 severity and
mortality in patients with chronic lymphocytic leukemia: A joint
study by ERIC, the European research initiative on CLL, and CLL
Campus. Leukemia. 34:2354–2363. 2020. View Article : Google Scholar
|
|
15
|
Agha M, Blake M, Chilleo C, Wells A and
Haidar G: Suboptimal response to COVID-19 mRNA vaccines in
hematologic malignancies patients. medRxiv. doi:
10.1101/2021.04.06.21254949 (Preprint). PubMed/NCBI
|
|
16
|
Poh AR, O'Donoghue RJ and Ernst M:
Hematopoietic cell kinase (HCK) as a therapeutic target in immune
and cancer cells. Oncotarget. 6:15752–15771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stack M, Sacco K, Castagnoli R, Livinski
AA, Notarangelo LD and Lionakis MS: BTK inhibitors for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic
review. Res Sq. doi: 10.21203/rs.3.rs-319342/v1 (Preprint).
PubMed/NCBI
|
|
18
|
Roosta Y, Behzadi F, Askari E, Raeisi M,
Danandeh Mehr A and Nouri-Vaskeh M: Concurrent chronic lymphocytic
leukemia and COVID-19: A comprehensive review of epidemiological,
diagnostic, and therapeutic challenges. Leuk Res Rep.
15:1002392021.PubMed/NCBI
|
|
19
|
Rossi D, Shadman M, Condoluci A, Brown JR,
Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E and
Ghia P: How we manage patients with chronic lymphocytic leukemia
during the SARS-CoV-2 pandemic. Hemasphere. 4:e4322020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jacque N and Leblond V: La leucémie
lymphoïde chronique: Mise au point. Presse Med. 48:807–815. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ali E, Badawi M, Abdelmahmuod E, Kohla S
and Yassin MA: Chronic lymphocytic leukemia concomitant with COVID
19: A case report. Am J Case Rep. 21:e9260622020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ting FI, Sacdalan DB, Cortez JL, Pacana
MAD and Jimeno C: COVID-19 in cancer patients can be challenging to
screen in a resource limited setting. Cancer Treat Res Commun.
25:1002142020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ye X, Xiao X, Li B, Zhu W, Li Y, Wu J,
Huang X, Jin J, Chen D, Jin J and Huang J: Low humoral immune
response and ineffective clearance of SARS-Cov-2 in a COVID-19
patient with CLL during a 69-day follow-up. Front Oncol.
10:12722020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alves Barbosa O, Guimarães Andrade T, de
Almeida Sousa MD and Correia JW: COVID-19 in a patient with chronic
lymphocytic leukaemia with pseudohypoxemia. Eur J Case Rep Intern
Med. 7:0017632020.PubMed/NCBI
|
|
25
|
Roeker LE, Knorr DA, Pessin MS, Ramanathan
LV, Thompson MC, Leslie LA, Zelenetz AD and Mato AR:
Anti-SARS-CoV-2 antibody response in patients with chronic
lymphocytic leukemia. Leukemia. 34:3047–3049. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sinisalo M, Aittoniemi J, Käyhty H and
Vilpo J: Vaccination against infections in chronic lymphocytic
leukemia. Leuk Lymphoma. 44:649–652. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Favresse J, Eucher C, Elsen M, Graux C,
Goebels P, Laffineur K, Nicolas JB, Dogné JM and Douxfils J:
Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two
patients with chronic lymphocytic leukemia. Br J Haematol.
190:e187–e189. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avanzato VA, Matson MJ, Seifert SN, Pryce
R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER,
Martens C, et al: Case study: Prolonged infectious SARS-CoV-2
shedding from an asymptomatic immunocompromised individual with
cancer. Cell. 183:1901–1912.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mato AR, Roeker LE, Lamanna N, Allan JN,
Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, et
al: Outcomes of COVID-19 in patients with CLL: A multicenter
international experience. Blood. 136:1134–1143. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baumann T, Delgado J and Montserrat E: CLL
and COVID-19 at the hospital clinic of Barcelona: An interim
report. Leukemia. 34:1954–1956. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Muntañola A, Villacampa G, Hernández-Rivas
JÁ, Alonso R, Mirás F, Osorio S, Baile M, Baltasar P, López Jiménez
J, Hernandez-Rodriguez I, et al: Clinical characteristics and
outcome of SARS-CoV-2 infection in admitted patients with chronic
lymphocytic leukemia from a single European country. Exp Hematol
Oncol. 9:372020. View Article : Google Scholar
|
|
32
|
Reda G, Noto A, Cassin R, Zamprogna G,
Borella C, Scarfò L, Farina L, Molteni A, Ghia P, Tedeschi A, et
al: Reply to ‘CLL and COVID-19 at the hospital clinic of Barcelona:
An interim report’ analysis of six hematological centers in
Lombardy: On behalf of CLL commission of Lombardy hematology
network (REL). Leukemia. 34:2531–2532. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang C, Wu Z, Li JW, Zhao H and Wang GQ:
The cytokine release syndrome (CRS) of severe COVID-19 and
Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the
key to reduce the mortality. Int J Antimicrob Agents.
55:1059542020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miossec P and Kolls JK: Targeting IL-17
and TH17 cells in chronic inflammation. Nat Rev Drug Discov.
11:763–776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Montserrat E: When CLL meets COVID-19.
Blood. 136:1115–1116. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song SH, Chen TL, Deng LP, Zhang YX, Mo
PZ, Gao SC, Hu WJ, Xiong Y and Ma ZY: Clinical characteristics of
four cancer patients with SARS-CoV-2 infection in Wuhan, China.
Infect Dis Poverty. 9:822020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niu A, McDougal A, Ning B, Safa F, Luk A,
Mushatt DM, Nachabe A, Zwezdaryk KJ, Robinson J, Peterson T, et al:
COVID-19 in allogeneic stem cell transplant: High false-negative
probability and role of CRISPR and convalescent plasma. Bone Marrow
Transplant. 55:2354–2356. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He
C, Xia WG, Zhang JX and Miao Q: Suppressed T cell-mediated immunity
in patients with COVID-19: A clinical retrospective study in Wuhan,
China. J Infect. 81:e51–e60. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
von Lilienfeld-Toal M, Vehreschild JJ,
Cornely O, Pagano L, Compagno F; EHA Infectious Disease Scientific
Working Group, ; Hirsch HH: Frequently asked questions regarding
SARS-CoV-2 in cancer patients-recommendations for clinicians caring
for patients with malignant diseases. Leukemia. 34:1487–1494. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Helleberg M, Niemann CU, Moestrup KS, Kirk
O, Lebech AM, Lane C and Lundgren J: Persistent COVID-19 in an
immunocompromised patient temporarily responsive to two courses of
remdesivir therapy. J Infect Dis. 222:1103–1107. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Langerbeins P, Fürstenau M, Gruell H,
Klein F, Persigehl T, Rybniker J, Seeger-Nukpezah T, Kochanek M,
Hallek M, Eichhorst B, et al: COVID-19 complicated by parainfluenza
co-infection in a patient with chronic lymphocytic leukemia. Eur J
Haematol. 105:508–511. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin L, Lu L, Cao W and Li T: Hypothesis
for potential pathogenesis of SARS-CoV-2 infection-a review of
immune changes in patients with viral pneumonia. Emerg Microbes
Infect. 9:727–732. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK,
Ng MH, Chan P, Wong KC, Leung CB and Cheng G: Use of convalescent
plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol
Infect Dis. 24:44–46. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rada M, Qusairy Z, Massip-Salcedo M and
Macip S: Relevance of the bruton tyrosine kinase (BTK) as a target
for COVID-19 therapy. Mol Cancer Res. 19:549–554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chong EA, Roeker LE, Shadman M, Davids MS,
Schuster SJ and Mato AR: BTK Inhibitors in cancer patients with
COVID-19: ‘The winner will be the one who controls that chaos’
(Napoleon Bonaparte). Clin Cancer Res. 26:3514–3516. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Treon SP, Castillo JJ, Skarbnik AP,
Soumerai JD, Ghobrial IM, Guerrera ML, Meid K and Yang G: The BTK
inhibitor ibrutinib may protect against pulmonary injury in
COVID-19-infected patients. Blood. 135:1912–1915. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Castillo JJ, Gustine JN, Meid K, Dubeau T,
Severns P and Treon SP: Ibrutinib withdrawal symptoms in patients
with Waldenström macroglobulinemia. Haematologica. 103:e307–e310.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun C, Tian X, Lee YS, Gunti S, Lipsky A,
Herman SE, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, et al:
Partial reconstitution of humoral immunity and fewer infections in
patients with chronic lymphocytic leukemia treated with ibrutinib.
Blood. 126:2213–2219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
de Weerdt I, Hofland T, de Boer R, Dobber
JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F,
Hoogendoorn M, Velders GA, et al: Distinct immune composition in
lymph node and peripheral blood of CLL patients is reshaped during
venetoclax treatment. Blood Adv. 3:2642–2652. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Riches JC, Davies JK, McClanahan F, Fatah
R, Iqbal S, Agrawal S, Ramsay AG and Gribben JG: T cells from CLL
patients exhibit features of T-cell exhaustion but retain capacity
for cytokine production. Blood. 121:1612–1621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Di Ciaccio P, McCaughan G, Trotman J, Ho
PJ, Cheah CY, Gangatharan S, Wight J, Ku MH, Quach H, Gasiorowski
R, et al: Australian and New Zealand consensus statement on the
management of lymphoma, chronic lymphocytic leukaemia and myeloma
during the COVID-19 pandemic. Intern Med J. 50:667–679. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cordoba R: Bringing hospital care closer
to patients amidst COVID-19. Lancet Haematol. 7:e6372020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
American Society of Hematology (ASH), .
COVID-19 and CLL: Frequently asked questions. ASH; Washington, DC:
2020, http://www.hematology.org/covid-19/covid-19-and-cllLast
updated February 2, 2021.
|
